TOKYO, Oct. 02, 2025 — A.D.A.M. Innovations Co. (“A.D.A.M. Innovations”), a prominent Japanese company specializing in genomics and AI, has officially unveiled GeneLink. This innovative advertising platform combines genetics, lifestyle data, and artificial intelligence to usher in a new age of highly targeted marketing.
GeneLink marks a significant change in advertising technology, transcending traditional demographic and behavioral targeting by incorporating biological predispositions as the cutting edge of personalization. Offering a novel choice compared to current ad-tech solutions that rely on demographics and behavior, GeneLink leverages the most extensive genomic database of the Japanese populace, allowing brands to connect with consumers more profoundly and genuinely, all while upholding privacy and achieving quantifiable outcomes.
“Through GeneLink, we are doing more than just evolving advertising; we are reimagining the way brands interact with individuals,” stated Michel Mommejat, President of A.D.A.M. Innovations. “By integrating AI with genetic and lifestyle information, GeneLink provides marketers with unparalleled accuracy, simultaneously offering individuals genuine worth, confidence, and incentives for sharing their data.”
Main Attributes of GeneLink
- Accurate Genetic & Lifestyle Targeting: AI-powered targeting that uses biological, metabolic, and wellness data, customized for each person’s genetic inclinations.
- Built-in Privacy: Operates on consent, features encryption, anonymization, and adheres completely to regulatory standards.
- Collaborative Economy Framework: Participants accrue GeneLife Points, redeemable for health and wellness items and services via the GeneLife application, with plans for future integration into other rewards schemes.
- Tailored Offerings for Marketers: DNA-guided product trials, in-application promotions, resemblance modeling, and bespoke genomic audience segmentation.
- Distinct Genomic Edge: Supported by the largest genomic dataset of the Japanese populace, providing unparalleled insights and accuracy unavailable to any other ad-tech platforms.
In contrast to conventional ad-tech platforms that profit from clicks, GeneLink repurposes advertising to foster wellness, disease prevention, and improved health, guaranteeing that benefits are returned to individuals, brands, and the broader community.
Initially debuting in Japan, GeneLink plans to progressively extend its global reach, introducing its precise marketing system to additional regions.
For further details, kindly visit:
Regarding A.D.A.M. Innovations Co.
Established in Tokyo in 2004, A.D.A.M. Innovations stands as a leader in genomics, AI, and customized health solutions. The firm creates advanced technologies covering consumer genetics, clinical diagnostic tools, and AI-powered research and development data platforms. To date, A.D.A.M. Innovations has performed over 2.8 million genetic analyses and manages the most extensive R&D genomic database concerning the Japanese populace.
Note: Genesis Healthcare Co. will adopt the new name A.D.A.M. Innovations Co. as of Nov. 1, 2025.
Concerning GeneLife and GeneLife Points
GeneLife serves as A.D.A.M. Innovations’ consumer-facing brand. GeneLife provides direct genetic testing to individuals via at-home kits and online retail platforms. Holding a 74% market share (per Fuji Kimera), GeneLife is the dominant force in its sector, offering bespoke health and wellness information to foster improved lifestyles and extended lifespans. Through its mobile app, GeneLife compensates its users with GeneLife Points, providing motivation for involvement in R&D initiatives, participation in marketing efforts, and furthering progress in personalized health and wellness.
Corporate inquiries:
Email:
Media Contacts: Crocker Coulson
Email:
+1 (646) 652-7185
